Download the Whitepaper
Maximizing the Potential of Continuous Glucose Monitoring in Clinical Trials
Maximizing the Potential of Continuous Glucose Monitoring in Clinical Trials
Insights, Challenges, and Regulatory Considerations for Applying CGM in Clinical Trials
When persons enroll in clinical trials that investigate therapies impacting glycemic patterns, it is essential to closely monitor glucose levels. This is where continuous glucose monitoring (CGM) can be a useful tool in assessing overall glycemic patterns and may help reduce the risks of adverse events like hypoglycemia.
In this whitepaper, Medpace experts explore key considerations for implementing CGM in clinical trials with an eye on regulatory guidance.
Your Diabetic Breakthrough Starts Here
Endorcrine & Metabolic CRO
With a successful track record of approvable NDA submissions, deep therapeutic expertise and decades of experience, Medpace can successfully navigate the operational complexities and regulatory scrutiny that endocrine and metabolic development programs often face. We have experience in recruiting historically difficult and highly competitive patient populations (both adult and pediatric), including patients with type 1 and type 2 diabetes.
At Medpace, we understand that patient engagement in diabetes trials can be challenging, with factors such as long study durations, glucose monitoring requirements, and complex drug regimens contributing to patient drop-out. Our team has the knowledge and tools to implement retention strategies that help mitigate these risks, ensuring studies run smoothly and generate high-quality data.
